Durable anti-tumor activity was also observed in patients with anti-PD-1-naive non-melanoma skin cancers with a median (range) duration of response of 7.3 (1.9–23.1) months, with responses observed in cutaneous squamous cell carcinoma (11 out of 17; ORR 64.7%), Merkel cell carcinoma (three out of four; ORR 75.0%), basal cell carcinoma (one out of four; ORR 25.0%), and angiosarcoma (four out of six; ORR 66.7%).80 The gene discussed is PDCD1; the disease is neoplasm.